| Laura Kisloff, | |
|
1 Nolte Dr, Ste 170, Kittanning, PA 16201-7111 | |
| (724) 548-2283 | |
| Not Available |
| Full Name | Laura Kisloff |
|---|---|
| Gender | Female |
| Speciality | Pediatrics |
| Location | 1 Nolte Dr, Kittanning, Pennsylvania |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1760485973 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208000000X | Pediatrics | MD073086L (Pennsylvania) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Laura Kisloff, 11279 Perry Hwy, Ste 450, Wexford, PA 15090-9381 Ph: () - | Laura Kisloff, 1 Nolte Dr, Ste 170, Kittanning, PA 16201-7111 Ph: (724) 548-2283 |
News Archive
Each day, 10,000 baby boomers retire and begin receiving Medicare and Social Security benefits. And while five workers supported the benefits of each retiree in 1960, there will be only two workers funding each retiree by 2030. Those who dismiss long-term budget projections should re-read the last paragraph. The retirement of 77 million baby boomers into Social Security and Medicare is not a theoretical projection. Demography is destiny (Sen. Rob Portman, R-Ohio, 7/21).
Aduro BioTech, a clinical-stage immunotherapy company, announced today the issuance of two important patents, the formation of a distinguished scientific advisory board, the addition of key members to its Board of Directors, and the reporting of preliminary top line long-term survival data from a Phase 1 clinical trial with 2 year follow-up.
Research projects in the areas of mathematics and biochemistry scored top marks this evening, as Tim Kunisky of Livingston, NJ and the team of Benjamin Song and Quan (Jack) Chen of Audubon, PA received the highest honors at the Region Five Finals of the 2009 Siemens Competition in Math, Science & Technology, the nation's premier high school science competition.
XenoPort, Inc. announced today that it has initiated a Phase 2 clinical trial of XP23829, its proprietary investigational next-generation fumaric acid product candidate. The trial is a multi-center, randomized, double-blind, placebo-controlled study designed to assess the efficacy and safety of XP23829 as a potential treatment of patients with moderate-to-severe chronic plaque-type psoriasis.
› Verified 2 days ago
Thomas Lynch, Pediatrics Medicare: Not Enrolled in Medicare Practice Location: 1 Nolte Dr, Ste 170, Kittanning, PA 16201 Phone: 724-548-2283 | |
Stephen Fowler, Pediatrics Medicare: Not Enrolled in Medicare Practice Location: 1 Nolte Dr, Ste 170, Kittanning, PA 16201 Phone: 724-548-2283 | |
Suzanne Reitz, MD Pediatrics Medicare: Not Enrolled in Medicare Practice Location: 1 Nolte Dr, Ste 170, Kittanning, PA 16201 Phone: 724-548-2283 Fax: 724-543-4380 | |
Joann Nickleach, Pediatrics Medicare: Not Enrolled in Medicare Practice Location: 1 Nolte Dr, Ste 170, Kittanning, PA 16201 Phone: 724-548-2283 | |
Donald J Vigliotti, MD Pediatrics Medicare: Not Enrolled in Medicare Practice Location: 1 Nolte Dr, Ste 107, Kittanning, PA 16201 Phone: 724-548-2283 Fax: 724-543-4380 | |
Kiran Bhat, MD Pediatrics Medicare: Not Enrolled in Medicare Practice Location: 1 Nolte Dr, Ste 170, Kittanning, PA 16201 Phone: 724-548-2283 Fax: 724-543-4380 | |
Kenneth Keppel, Pediatrics Medicare: Not Enrolled in Medicare Practice Location: 1 Nolte Dr, Ste 170, Kittanning, PA 16201 Phone: 724-548-2283 |